Jenburkt Pharmaceuticals Share Price
1037.80-2.25 (-0.22%)
-12.66% past 1 Year
Jenburkt Pharmaceuticals Limited is an India-based company engaged pharmaceutical formulations. The Company is engaged in manufacturing and marketing of speciality and pharmaceutical formulations and healthcare products. The Company manufactures products
Corporate filings & documents
Announcements
Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June 2026.
4 weeks agoNewspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June 2026.
4 weeks agoStandalone Unaudited Financial Results for the quarter ended on 30th June 2026.
4 weeks agoStandalone Unaudited Financial Results for the quarter ended on 30th June 2026.
4 weeks agoOutcome of the Board Meeting held today on 06th August 2026.
4 weeks agoOutcome of the Board Meeting held today on 06th August 2026.
4 weeks agoPursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 we are enclosing herewith clippings of the Newspaper publication for Notice of the 41st AGM of the Company.
1 month agoPursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 we are enclosing herewith clippings of the Newspaper publication for Notice of the 41st AGM of the Company.
1 month agoNotice of the 41st Annual General Meeting of the Company Schedule to be held on Friday 04th September 2026 through VC/OAVM.
1 month agoNotice of the 41st Annual General Meeting of the Company Schedule to be held on Friday 04th September 2026 through VC/OAVM.
1 month agoSubmission of the Annual Report for the FY 2025-26 containing Audited Standalone Financial Statements Auditors Report and Directors Report and the Notice convening 41st Annual General Meeting of the Company.
1 month agoSubmission of the Annual Report for the FY 2025-26 containing Audited Standalone Financial Statements Auditors Report and Directors Report and the Notice convening 41st Annual General Meeting of the Company.
1 month agoJenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve standalone unaudited financial results for the quarter ended on 30th June 2026.
1 month agoJenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 inter alia to consider and approve standalone unaudited financial results for the quarter ended on 30th June 2026.
1 month agoIntimation of shifting of Registered Office of the Company within the local limits of city of Mumbai.
1 month agoIntimation of shifting of Registered Office of the Company within the local limits of city of Mumbai.
1 month agoCertificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 30th June 2026
1 month agoCertificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 30th June 2026
1 month agoIntimation of Closure of Trading Window of Jenburkt Pharmaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations 2015.
2 months agoIntimation of Closure of Trading Window of Jenburkt Pharmaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations 2015.
2 months agoNewspaper Advertisement for giving notice for the purpose of transfer of unclaimed dividend and corresponding equity shares of the Company to IEPFA.
3 months agoAnnual Secretraial Compliance Report for the financial year ended 31st March 2026.
3 months agoThe Company has fixed Friday 28th August 2026 as the Record date for the Payment of Dividend for the Financial Year 2025-26 as well as cut-off date for Remote e-voting and e-voting during the 41st AGM.
4 months agoNewspaper Publication for standalone Audited financial results for the quarter and financial year ended on 31st March 2026.
4 months agoNewspaper Publication for standalone Audited financial results for the quarter and financial year ended on 31st March 2026.
4 months agoThe Board of Director of the Company recommeded a dividend of Rs.20.70 (207%) per equity share of Rs.10/- each on 4413300 equity shares of the Company for the financial year 2025-26 Subject to the approval of the menbers it the ensuing 41st AGM of the Company.
4 months agoThe Board of Director of the Company recommeded a dividend of Rs.20.70 (207%) per equity share of Rs.10/- each on 4413300 equity shares of the Company for the financial year 2025-26 Subject to the approval of the menbers it the ensuing 41st AGM of the Company.
4 months agoRe-appointment of Whole Time Director and CFO of the Company subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.
4 months agoRe-appointment of Whole Time Director and CFO of the Company subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.
4 months agoStandalone audited financial reults of the Company for the quarter and financial year ended on 31st March 2026.
4 months agoOutcome of Board Meeting Held on 05th May 2026.
4 months agoJenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 inter alia to consider and approve the audited results for the quarter and financial year ended on 31st March 2026 and to consider recommendation of dividend if any.
4 months agoJenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 inter alia to consider and approve the audited results for the quarter and financial year ended on 31st March 2026 and to consider recommendation of dividend if any.
4 months agoPursuant to SEBI Circular dated 10th August 2021 we hereby confirm that for the financial year ended 31st March 2026 Jenburkt pharmaceuticals Limited is "not a large corporate" as per applicability criteria mentioned in clause 2.11 of chapter XII therein.
4 months agoPursuant to SEBI Circular dated 10th August 2021 we hereby confirm that for the financial year ended 31st March 2026 Jenburkt pharmaceuticals Limited is "not a large corporate" as per applicability criteria mentioned in clause 2.11 of chapter XII therein.
4 months agoCertificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.
5 months agoCertificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.
5 months agoIntimation of closure of trading window of Jenburkt Phamaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations 2015.
5 months agoIntimation of closure of trading window of Jenburkt Phamaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations 2015.
5 months agoNewspaper Publication for Unaudited statndalone financial Statement for the quarter and nine months ended on 31st Decemeber 2025.
7 months agoStandalone Unaudited financial results for the quarter and nine months ended on 31st December 2025.
7 months agoOutcome of the Board Meeting held today on 03rd February 2026.
7 months agoJenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 inter alia to consider and approve standalone unaudited financial results for the quarter and nine months ended On 31st December 2025.
7 months agoCertificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31.12.2025.
8 months agoIntimation of closure of trading window of Jenburkt Pharmaceuticals Limited as per the SEBI (Prohibition of Insider Trading) Regulations 2015.
8 months agoNewspaper Publication for Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2025.
10 months agoStandalone Unaudited financial results for the quarter and half year ended on 30th September 2025.
10 months agoOutcome of the Board Meeting held today on 28th October 2025.
10 months agoCertificate purusant to Regulation 74(5) of the SEBI (D&P) Regulations 2018 for the quarter ended on 30th September 2025.
11 months agoJenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2025 inter alia to consider and approve standalone unaudited financial results for the quarter and half year ended on 30th September 2025.
11 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2026-08-28
Dividend
20.7
2025-07-11
Dividend
18.0
2024-07-23
Dividend
15.3
2023-07-19
Dividend
14.4
Company details
Registered office
14th Floor, Unicorn Dattaji Salvi Marg, Off Veera Desai Road Andheri (West) Mumbai Maharashtra PIN: 400053 Tel No: 022-67603603 Fax No: 022-66943127 Email: [email protected] / [email protected] Internet: www.jenburkt.com
Registrars
Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093(old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059Tel: + 91 21 626 38200Fax: Office No S6-2, 6th Floor, Pinnacle Business Park Next to Ahura Centre, Mahakali Caves Road Andheri (E) PIN: Tel No: 91-022-62638200 Fax No: 91-022-62638299 Email: [email protected]
Management
Ashish U Bhuta, Chairman & Managing Director
Ashish U Bhuta, Chairman & Managing Director
Dilip H Bhuta, Whole Time Director & Chief Financial Officer
Hina R Mehta, Non Executive Independent Director
Sumit A Thakkar, Non Executive Independent Director
Krishnan Subharaman, Non Executive Independent Director
Pankaj A Dantwala, Non Executive Independent Director
Ashish R Shah, Senior Vice President, Company Secretary & Compliance Officer
Details
BSE 524731
NSE JENBURPH
ISIN INE354A01013